Xeris Biopharma’s (XERS) Positioning Strengthens After Reaching Product Pipeline Milestone

Xeris Biopharma Holdings Inc. (NASDAQ:XERS) is among the hidden multibagger stocks to invest in. On Dec. 1, 2025, XERS announced progress on one of its pipeline products. The United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for Xeris Pharmaceuticals, a subsidiary of Xeris Biopharma Holdings. The Notice pertains to the XP-8121 formulation, a once-a-week subcutaneous injection that utilizes Xeris’ proprietary XeriSol platform.

The company has pointed out that existing oral levothyroxine shows variable absorption in the gastrointestinal tract. XP-8121 solves this problem through the injection, making it viable. The CEO of the company, John Shannon, not only highlighted the achievement of this critical milestone but also praised the company’s XeriSol platform:

“We believe XP-8121 has tremendous potential to solve an unmet medical need for hypothyroidism, and this patent represents a key milestone in strengthening our intellectual property protection around this important pipeline program. It further demonstrates the ability of our XeriSol® platform to enable the development of difficult-to-formulate drugs into subcutaneous injections.”

Xeris continues to pursue additional IP protection for levothyroxine (LT4) alongside the above developments.

Xeris Biopharma Holdings Inc. (NASDAQ:XERS) is a fast-growing biopharmaceutical company with three commercially available medications. Recorlev treats endogenous Cushing’s syndrome, Gvoke helps treat severe hypoglycemia, while Keveyis is a therapy for primary periodic paralysis.

While we acknowledge the risk and potential of XERS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than XERS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT:  Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy and 30 Most Fantastic Stocks Every Investor Should Pay Attention To.

Disclosure: None. This article is originally published at Insider Monkey.